Mycobacterium tuberculosis phosphoantigens (HMBPP) (HMBPP)

Mycobacterium tuberculosis phosphoantigens are a class of low-molecular-weight phosphorylated metabolites, primarily (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), produced via the methylerythritol phosphate (MEP) pathway (Constant et al., 1994; Morita et al., 2007). These molecules serve as potent non-peptide antigens that are specifically recognized by human Vγ9Vδ2 T cells, a subset of gamma-delta T cells involved in the early immune response to pathogens (Eberl et al., 2003). Upon infection, M. tuberculosis releases HMBPP, which binds to the intracellular B30.2 domain of Butyrophilin 3A1 (BTN3A1) in host cells (Gu et al., 2020). This binding triggers a conformational change and association with Butyrophilin 2A1 (BTN2A1), leading to the activation and proliferation of Vγ9Vδ2 T cells and the subsequent release of pro-inflammatory cytokines like IFN-γ and TNF-α (Rigau et al., 2020). In a therapeutic context, synthetic phosphoantigens or drugs that increase endogenous phosphoantigen levels, such as aminobisphosphonates, are explored as immunotherapies for both tuberculosis and various malignancies to harness the potent anti-tumor and anti-microbial activity of γδ T cells (Bennouna et al., 2010; Gober et al., 2003). These agents aim to bridge innate and adaptive immunity by rapidly mobilizing a large population of T cells without the need for MHC-restricted antigen presentation (Pauza et al., 2018). However, therapeutic challenges include the short half-life of these small molecules in vivo and the potential for T-cell exhaustion following repeated stimulation. Monitoring the expansion of Vγ9Vδ2 T cells and cytokine levels serves as a primary method for assessing the efficacy of phosphoantigen-based therapies.

Other names

(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphateHMB-PPPhosphoantigensMEP pathway metabolitesIsopentenyl pyrophosphate (IPP) precursors

Agonism of Vγ9Vδ2 T cells via binding to the intracellular B30.2 domain of Butyrophilin 3A1 (BTN3A1) and subsequent interaction with Butyrophilin 2A1 (BTN2A1).